• KOL
    • Neonatal Lupus
    • Jill P Buyon
    • Jill P Buyon: Influence Statistics

      Jill P Buyon

      Jill P Buyon

      Show email address

      Department of Medicine, NYU Grossman School of Medicine, New York, 10016, USA | Division of Rheumatology Department of Medicine New York University Grossman School of Medicine ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Jill P Buyon:Expert Impact

      Concepts for whichJill P Buyonhas direct influence:Neonatal lupus,Systemic lupus erythematosus,Heart block,Lupus erythematosus,Congenital heart block,Systemic lupus,Lupus nephritis,Cardiac manifestations.

      Jill P Buyon:KOL impact

      Concepts related to the work of other authors for whichfor which Jill P Buyon has influence:Systemic lupus erythematosus,Lupus nephritis,Sle patients,Antiphospholipid syndrome,Autoimmune diseases,Endothelial cells,Rheumatoid arthritis.

      KOL Resume for Jill P Buyon

      Year
      2022

      Department of Medicine, NYU Grossman School of Medicine, New York, 10016, USA

      NYU Langone Health, New York, NY

      2021

      Division of Rheumatology, Department of Medicine, New York University Grossman School of Medicine, New York, NY

      Grossman School of Medicine, New York University, New York, New York, USA

      2020

      New York University School of Medicine, New York, NY (R. Clancy, C.K.P., R. Cohen, M.M., B.J.W., A.S., P.M.I., J.P.B.).

      2019

      Medicine, NYU School of Medicine, New York, New York, United States

      Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy

      2018

      Division of Rheumatology, Department of Medicine, New York School of Medicine, New York City, New York, USA

      2017

      Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, New York.

      36 New York School of Medicine, New York, US.

      New York University Langone Medical Center, New York, New York

      Due to the number of contributing authors, the affiliations are provided in the Supplemental Material.

      2016

      NYU School of Medicine, New York, New York, USA

      Department of Epidemiology and Population Health, Division of Biostatistics, Albert Einstein College of Medicine, Bronx, NY

      2015

      New York University School of Medicine Division of Rheumatology Department of Medicine New York NY USA

      Dr. Buyon has received consulting fees, speaking fees, and/or honoraria from Novo Nordisk, Immunoarray, GlaxoSmithKline, Biogen Idec, Acthar, Genentech, ER Squibb, Anthera, Questcor, Argos, Exagen, and Nicox (less than $10,000 each).

      Johns Hopkins University School of Medicine, Baltimore, Maryland; and University of Illinois at Chicago, Chicago, Illinois.

      2014

      New York University, New York, NY, USA.

      2013

      Department of Medicine, New York University School of Medicine, New York, NY 10016; and

      New York University Langone Medical Center New York New York

      Nyu School of Medicine

      2012

      New York University Langone School of Medicine, New York, New York

      2011

      Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, NY 10016; and

      New York University Medical Center, New York, New York 10016. Electronic address:

      Professor of Pediatrics, Chief, Pediatric Rheumatology, Department of Pediatrics, University of Kansas Medical Center, Kansas City, Kansas

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Jill P Buyon is among the top experts in the world.
      Concept World rank
      child cutaneous #1
      “pr‐fect” solution #1
      immunoglobulin mother #1
      chapter 51 #1
      women mctd #1
      fetus degree block #1
      antibody insult #1
      exon smaller protein #1
      quantitative pcr immunofluorescence #1
      yater #1
      enzyme unpel #1
      literature mobitz type #1
      ribonucleoproteins risk #1
      igg apoptotic cells #1
      communities lupus #1
      life chb #1
      seconddegree block presentation #1
      asians responses #1
      binding maternal antibodies #1
      response mmf #1
      cr3 tlr #1
      s5s6 alpha1d #1
      tissue expression mcp #1
      –bound apoptotic cardiocytes #1
      sle asymptomatic mothers #1
      neonatal lupus 80 #1
      utero absence #1
      unpel bait #1
      difference doppler interval #1
      chb early institution #1
      cardiac neonatal lupus #1
      fetuses chb myocarditis #1
      amino acid 200–239 #1
      doppler pulsed arrhythmias #1
      protein dimer formation #1
      cchb maternal antibodies #1
      ro60 p133 #1
      clinical efficacy hydroxychloroquine #1
      fetal hearts phenotype #1
      60 titers cardiac #1
      presence tii #1
      fetal conduction #1
      nle hepatobiliary #1
      aro sensitivity #1
      risk cutaneous disease #1
      ica superfusion #1
      presentation degree block #1
      mobitz type fetuses #1
      block congenital #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Jill P Buyon

      KOL-Index: 22715

      OBJECTIVE: To identify the fine specificity patterns of maternal anti-SS-A/Ro and anti-SS-B/La antibodies that are associated with the birth of a child with transient or permanent manifestations of neonatal lupus syndromes, and to suggest a predictor algorithm for use in counseling.

      METHODS: Sera were obtained from 4 groups of mothers: 57 whose children had congenital heart block, 12 whose children had transient dermatologic or hepatic manifestations of neonatal lupus but no detectable ...

      Known for Neonatal Lupus | Heart Block | Mothers Children | Immunosorbent Assay | Anti Antibodies
      KOL-Index: 17837

      BACKGROUND: Over 20% of pregnancies in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid antibodies (APL) result in an adverse pregnancy outcome (APO) related to abnormal placentation. The ability to identify, early in pregnancy, patients who are destined for poor outcomes would significantly impact care of this high-risk population. In nonautoimmune patients, circulating angiogenic factors are dysregulated in disorders of placentation, such as preeclampsia (PE) ...

      Known for Antiphospholipid Antibodies | Adverse Outcomes | Pregnancy Patients | Sflt1 Plgf | Angiogenic Factor
      KOL-Index: 17027

      OBJECTIVES: To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal antibody that neutralises membrane and soluble B-cell activating factor (BAFF).

      METHODS: This randomised, placebo-controlled study enrolled 1124 patients with moderate-to-severe systemic lupus erythematosus (SLE) (Safety of Estrogens in Lupus Erythematosus National Assessment- SLE Disease Activity Index ≥6 at baseline). Patients received standard of care plus subcutaneous study drug, starting with a ...

      Known for Subcutaneous Tabalumab | Monoclonal Antibody | Activating Factor | Antinuclear Antibodies | Lupus Erythematosus
      KOL-Index: 15160

      OBJECTIVE: The Manhattan Lupus Surveillance Program (MLSP) is a population-based registry designed to determine the prevalence of systemic lupus erythematosus (SLE) in 2007 and the incidence from 2007 to 2009 among residents of New York County (Manhattan), New York, and to characterize cases by race/ethnicity, including Asians and Hispanics, for whom data are lacking.

      METHODS: We identified possible SLE cases from hospital records, rheumatologist records, and administrative databases. ...

      Known for New York | Systemic Lupus | Incidence Prevalence | Race Ethnicity | Asians Hispanics
      KOL-Index: 14778

      OBJECTIVE: To investigate which serologic and clinical findings predict adverse pregnancy outcome in patients with antiphospholipid antibody (aPL) and to test the hypothesis that a pattern of clinical and serologic variables can identify women at highest risk of adverse pregnancy outcome.

      METHODS: Women enrolled in a multicenter prospective observational study of risk factors for adverse pregnancy outcome in patients with aPL (lupus anticoagulant [LAC], anticardiolipin antibody [aCL], ...

      Known for Adverse Pregnancy Outcome | Anticardiolipin Antibody | Patients Lac | Antiβ2 Gpi | Lupus Anticoagulant
      KOL-Index: 14041

      It is often difficult to differentiate between an exacerbation of systemic lupus erythematosus (SLE) and intercurrent pre-eclampsia in a patient with SLE since the manifestations of both entities include proteinuria and hypertension. This study was undertaken to determine wether serum C3 and C4 values can help distinguish SLE activity from pre-eclampsia. In 21 nonpregnant women of child-bearing age, the mean C3 level was 124 +/- 5 mg/dl and the mean C4 was 31 +/- 1 mg/dl. In 24 normal ...

      Known for Pregnancy Women | Systemic Lupus | Sle Activity | Serum Complement | Hypertension Proteinuria
      KOL-Index: 12998

      OBJECTIVE: Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.

      METHODS: Information and blood samples were obtained in a cross-sectional study from patients with SLE (n = 308) and other rheumatologic diseases (n = 389) from 25 clinical sites (84% female, 68% Caucasian, 17% ...

      Known for C1q Anti | Lupus Erythematosus | Renal Involvement | Patients Sle | Studies Complement
      KOL-Index: 12967

      OBJECTIVE: To test the hypothesis that during exacerbations of systemic lupus erythematosus (SLE), endothelial cells are activated to increase their expression of adhesion molecules.

      METHODS: Endothelial cell expression of E-selectin, vascular cell adhesion molecule 1 (VCAM-1), and intercellular adhesion molecule 1 (ICAM-1) was quantitated immunohistochemically in 20 biopsy specimens from nonlesional, non-sun-exposed skin from 16 SLE patients. Disease activity was evaluated with the SLE ...

      Known for Adhesion Molecules | Endothelial Cell | Systemic Lupus | Patients Sle | Vcam1 Icam1
      KOL-Index: 12628

      OBJECTIVE: Identifying the frequency of recurrent cardiac manifestations of neonatal lupus (NL) in a second child is critical to understanding the pathogenesis of anti-SSA/Ro-mediated injury and would improve counseling strategies regarding future pregnancies and power the design of clinical prevention trials. Accordingly, this study was undertaken to address the recurrence rates of cardiac NL and associated risk factors in a large US-based cohort.

      METHODS: Families enrolled in the ...

      Known for Recurrence Rate | Neonatal Lupus | Cardiac Manifestations | Newborn Infant | Birth Child
      KOL-Index: 12616

      BACKGROUND: Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable.

      METHODS: We conducted a 24-week randomized, open-label, noninferiority trial comparing oral mycophenolate mofetil (initial dose, 1000 mg per day, increased to 3000 mg per day) with monthly intravenous cyclophosphamide (0.5 g per square meter of body-surface area, increased to 1.0 g per square meter) as ...

      Known for Mycophenolate Mofetil | Intravenous Cyclophosphamide | Lupus Nephritis | 24 Weeks | Complete Remission
      KOL-Index: 12537

      BACKGROUND: Oral contraceptives are rarely prescribed for women with systemic lupus erythematosus, because of concern about potential negative side effects. In this double-blind, randomized, noninferiority trial, we prospectively evaluated the effect of oral contraceptives on lupus activity in premenopausal women with systemic lupus erythematosus.

      METHODS: A total of 183 women with inactive (76 percent) or stable active (24 percent) systemic lupus erythematosus at 15 U.S. sites were ...

      Known for Oral Contraceptives | Systemic Lupus Erythematosus | Deep Venous Thrombosis | 92 Women | Receiving Placebo
      KOL-Index: 12191

      BACKGROUND: Systemic lupus erythematosus (SLE) is associated with premature atherosclerosis but the mechanisms underlying this association are not understood. The role of endothelial dysfunction is hypothesized.

      METHODS: In predominantly non-Caucasian patients with SLE (N=119) and controls (N=71), carotid ultrasonography was performed and circulating endothelial cells (CECs), soluble endothelial protein C receptor and gene polymorphism at A6936G, soluble E-selectin (sE-selectin), and ...

      Known for Carotid Plaque | Systemic Lupus Erythematosus | Sle Patients | Soluble Selectin | Premature Atherosclerosis
      KOL-Index: 11892

      It has been reported that antiphospholipid autoantibodies do not recognize phospholipid alone, but rather the plasma protein beta 2-glycoprotein I (beta 2GPI), or a beta 2GPI-phospholipid complex. In vitro beta 2GPI binds to anionic phospholipids and inhibits the prothrombinase activity of procoagulant membranes. In light of the fact that lupus anticoagulants, a type of antiphospholipid antibody, have similar anticoagulant properties, the relationship of beta 2GPI to lupus anticoagulant ...

      Known for Lupus Anticoagulant Activity | Antiphospholipid Antibodies | Beta 2 | Inbred Balb | Autoimmune Diseases

      Key People For Neonatal Lupus

      Top KOLs in the world
      #1
      Jill P Buyon
      neonatal lupus heart block patients sle
      #2
      Lela A Lee
      neonatal lupus heart block maternal autoantibodies
      #3
      Thomas T Provost
      lupus erythematosus bullous pemphigoid ovarian cancer
      #4
      WILLIAM L Weston
      erythema multiforme atopic dermatitis neonatal lupus
      #5
      Morris Reichlin
      systemic lupus erythematosus antiro ssa lupus patients
      #6
      Earl Dean Silverman
      lupus erythematosus kawasaki disease juvenile rheumatoid arthritis

      Department of Medicine, NYU Grossman School of Medicine, New York, 10016, USA | Division of Rheumatology Department of Medicine New York University Grossman School of Medicine New York NY. | New York University School of Medicine, New York, New York,

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.